Cargando…

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer

This retrospective study examined magnetic resonance imaging (MRI)–derived tumor sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the association between SPH and reader-assessed morphological pattern (MP). In addition, association of SPH with pathologic complet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wen, Newitt, David C., Yun, Bo La, Jones, Ella F., Arasu, Vignesh, Wilmes, Lisa J., Gibbs, Jessica, Nguyen, Alex Anh-Tu, Onishi, Natsuko, Kornak, John, Joe, Bonnie N., Esserman, Laura J., Hylton, Nola M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Grapho Publications, LLC 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289243/ https://www.ncbi.nlm.nih.gov/pubmed/32548299 http://dx.doi.org/10.18383/j.tom.2020.00016

Ejemplares similares

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL
por: Li, Wen, et al.
Publicado: (2016)

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2020)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2022)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
por: Le, Nu N., et al.
Publicado: (2022)

MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
por: Jones, Ella F., et al.
Publicado: (2013)

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Wilmes, Lisa J., et al.
Publicado: (2016)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET
por: Hathi, Deep K., et al.
Publicado: (2020)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Jahani, Nariman, et al.
Publicado: (2019)

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis
por: Huang, Shih-ying, et al.
Publicado: (2018)

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
por: Li, Wen, et al.
Publicado: (2020)

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
por: Thakran, Snekha, et al.
Publicado: (2022)

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
por: Jones, Ella F., et al.
Publicado: (2019)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
por: Malyarenko, Dariya I., et al.
Publicado: (2020)

Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
por: Chitalia, Rhea, et al.
Publicado: (2022)

Agreement of Mammographic Measures of Volumetric Breast Density to MRI
por: Wang, Jeff, et al.
Publicado: (2013)

Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Galbán, Craig J., et al.
Publicado: (2015)

Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment
por: Cochran, Jeffrey M., et al.
Publicado: (2018)

A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy
por: Sutton, Elizabeth J., et al.
Publicado: (2020)

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Esserman, Laura J., et al.
Publicado: (2011)

Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial
por: Newitt, David C., et al.
Publicado: (2020)

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2022)

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
por: Clark, Amy S, et al.
Publicado: (2014)

Liposomal Spherical Nucleic Acids
por: Banga, Resham J., et al.
Publicado: (2014)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy for Colon Cancer
por: Roth, Marc T., et al.
Publicado: (2020)

Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
por: Le, Duc Thanh, et al.
Publicado: (2023)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k4spu58sa4bhhsc5km46mersk5